JP2013520173A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520173A5 JP2013520173A5 JP2012554069A JP2012554069A JP2013520173A5 JP 2013520173 A5 JP2013520173 A5 JP 2013520173A5 JP 2012554069 A JP2012554069 A JP 2012554069A JP 2012554069 A JP2012554069 A JP 2012554069A JP 2013520173 A5 JP2013520173 A5 JP 2013520173A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- antibody
- seq
- fibrosis
- pulmonary fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 25
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 17
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 16
- 206010016654 Fibrosis Diseases 0.000 claims description 14
- 230000004761 fibrosis Effects 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 12
- 230000003176 fibrotic effect Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 208000016192 Demyelinating disease Diseases 0.000 claims description 7
- 208000032612 Glial tumor Diseases 0.000 claims description 7
- 206010018338 Glioma Diseases 0.000 claims description 7
- 206010027476 Metastases Diseases 0.000 claims description 7
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 7
- 208000009956 adenocarcinoma Diseases 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 7
- 230000005907 cancer growth Effects 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 208000017169 kidney disease Diseases 0.000 claims description 7
- 230000009401 metastasis Effects 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 230000003959 neuroinflammation Effects 0.000 claims description 7
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 7
- 208000009174 transverse myelitis Diseases 0.000 claims description 7
- 208000029067 Neuromyelitis optica spectrum disease Diseases 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 6
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 6
- 206010006448 Bronchiolitis Diseases 0.000 claims description 5
- 208000029147 Collagen-vascular disease Diseases 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 5
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 201000010001 Silicosis Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 239000010425 asbestos Substances 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 201000009803 desquamative interstitial pneumonia Diseases 0.000 claims description 5
- 230000009610 hypersensitivity Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 5
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 230000000241 respiratory effect Effects 0.000 claims description 5
- 229910052895 riebeckite Inorganic materials 0.000 claims description 5
- 102100033336 Integrin beta-8 Human genes 0.000 claims description 4
- 206010067472 Organising pneumonia Diseases 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 claims description 4
- 108010021506 integrin beta8 Proteins 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30574910P | 2010-02-18 | 2010-02-18 | |
| US61/305,749 | 2010-02-18 | ||
| US201061428814P | 2010-12-30 | 2010-12-30 | |
| US61/428,814 | 2010-12-30 | ||
| PCT/US2011/025514 WO2011103490A2 (en) | 2010-02-18 | 2011-02-18 | INTEGRIN αVβ8 NEUTRALIZING ANTIBODY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016079967A Division JP6212159B2 (ja) | 2010-02-18 | 2016-04-13 | インテグリンαｖβ８中和抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013520173A JP2013520173A (ja) | 2013-06-06 |
| JP2013520173A5 true JP2013520173A5 (enExample) | 2014-04-24 |
Family
ID=44483602
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012554069A Pending JP2013520173A (ja) | 2010-02-18 | 2011-02-18 | インテグリンαｖβ８中和抗体 |
| JP2016079967A Expired - Fee Related JP6212159B2 (ja) | 2010-02-18 | 2016-04-13 | インテグリンαｖβ８中和抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016079967A Expired - Fee Related JP6212159B2 (ja) | 2010-02-18 | 2016-04-13 | インテグリンαｖβ８中和抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9290572B2 (enExample) |
| EP (2) | EP2536762A4 (enExample) |
| JP (2) | JP2013520173A (enExample) |
| KR (1) | KR101838763B1 (enExample) |
| CN (2) | CN105315370A (enExample) |
| AU (1) | AU2011217848B8 (enExample) |
| BR (1) | BR112012020790B1 (enExample) |
| CA (1) | CA2790488C (enExample) |
| MX (2) | MX375079B (enExample) |
| RU (1) | RU2565539C2 (enExample) |
| SG (1) | SG183356A1 (enExample) |
| WO (1) | WO2011103490A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011103490A2 (en) * | 2010-02-18 | 2011-08-25 | The Regents Of The University Of California | INTEGRIN αVβ8 NEUTRALIZING ANTIBODY |
| MX350335B (es) * | 2011-08-17 | 2017-09-04 | Univ California | Anticuerpos que enlazan alfa-v beta-8 integrina. |
| EP2844287A4 (en) * | 2012-05-02 | 2016-01-27 | Univ New York | METHOD FOR THE TREATMENT AND PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS AND RELATED DISEASES |
| WO2014165524A2 (en) | 2013-04-01 | 2014-10-09 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with avb8 integrin |
| ES2779412T3 (es) * | 2014-06-17 | 2020-08-17 | Medimmune Ltd | Anticuerpos Alfa-V Beta-8 mejorados |
| EP3009147A1 (en) | 2014-10-16 | 2016-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant glioblastoma |
| WO2017182834A1 (en) | 2016-04-19 | 2017-10-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating resistant glioblastoma |
| CN109862913B (zh) * | 2016-09-29 | 2023-09-05 | 加利福尼亚大学董事会 | 用于免疫疗法的αvβ8整联蛋白复合物的中和抗体 |
| CN112823167B (zh) | 2018-09-07 | 2025-07-15 | 辉瑞大药厂 | 抗-αvβ8抗体和组合物及其用途 |
| WO2020210650A1 (en) * | 2019-04-12 | 2020-10-15 | Medimmune, Llc | Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections |
| AU2021209117A1 (en) | 2020-01-15 | 2022-07-07 | The Regents Of The University Of California | Antibodies that bind integrin ανβ8 and uses thereof |
| TWI854088B (zh) * | 2020-01-27 | 2024-09-01 | 英商梅迪繆思有限公司 | 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體 |
| WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
| WO2024073372A2 (en) * | 2022-09-29 | 2024-04-04 | The Brigham And Women's Hospital, Inc. | Blocking itgb8 in neurodegenerative disease |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
| CN117126282B (zh) * | 2023-10-26 | 2024-01-12 | 迈威(上海)生物科技股份有限公司 | 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用 |
| CN117143241B (zh) * | 2023-10-26 | 2024-02-23 | 迈威(上海)生物科技股份有限公司 | 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5204445A (en) * | 1988-10-03 | 1993-04-20 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| AU8295491A (en) | 1990-06-29 | 1992-01-23 | Biosource Technologies Incorporated | Melanin production by transformed microorganisms |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0575554A1 (en) | 1991-03-14 | 1993-12-29 | Genentech, Inc. | Novel beta integrin subunit |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| ATE244306T1 (de) * | 1994-12-20 | 2003-07-15 | Merck Patent Gmbh | Monoklonaler antikörper gegen das alpha-v- integrin |
| CN1168741C (zh) * | 1998-01-23 | 2004-09-29 | 默克专利股份有限公司 | 抗αv整联蛋白单克隆抗体及其在抑制αvβ6整联蛋白与纤连蛋白附着中的应用 |
| ES2146552B1 (es) * | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| US6160099A (en) | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| WO2004043989A2 (en) | 2002-11-07 | 2004-05-27 | Medarex, Inc. | Human monoclonal antibodies to heparanase |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| KR101224235B1 (ko) | 2003-04-11 | 2013-01-25 | 메디뮨 엘엘씨 | 재조합 ｉｌ９ 항체 및 그의 용도 |
| JP4653660B2 (ja) | 2003-09-04 | 2011-03-16 | 独立行政法人理化学研究所 | ＴＧＦ−β活性化制御領域の切断面を認識する抗体 |
| EP1702071B1 (en) | 2003-12-31 | 2012-02-22 | Kalobios Inc. | Transactivation system for mammalian cells |
| ES2689328T3 (es) | 2004-01-07 | 2018-11-13 | Novartis Vaccines And Diagnostics, Inc. | Anticuerpo monoclonal M-CSF-específico y usos del mismo |
| US7981843B2 (en) | 2004-01-20 | 2011-07-19 | Kalobios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| CN1961003B (zh) * | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| PL2343380T3 (pl) | 2004-11-16 | 2020-03-31 | Humanigen, Inc. | Wymiana kasety dla regionu zmiennego immunoglobuliny |
| GB0520068D0 (en) * | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| WO2008141274A1 (en) * | 2007-05-11 | 2008-11-20 | Centocor, Inc. | Anti-alpha v immunoliposome composition, methods and uses |
| US20110250203A1 (en) | 2008-08-29 | 2011-10-13 | Symphogen A/S | Anti-cd5 antibodies |
| WO2011103490A2 (en) * | 2010-02-18 | 2011-08-25 | The Regents Of The University Of California | INTEGRIN αVβ8 NEUTRALIZING ANTIBODY |
| MX350335B (es) * | 2011-08-17 | 2017-09-04 | Univ California | Anticuerpos que enlazan alfa-v beta-8 integrina. |
-
2011
- 2011-02-18 WO PCT/US2011/025514 patent/WO2011103490A2/en not_active Ceased
- 2011-02-18 KR KR1020127024165A patent/KR101838763B1/ko not_active Expired - Fee Related
- 2011-02-18 EP EP11745373.8A patent/EP2536762A4/en not_active Withdrawn
- 2011-02-18 BR BR112012020790-3A patent/BR112012020790B1/pt not_active IP Right Cessation
- 2011-02-18 RU RU2012139829/10A patent/RU2565539C2/ru active
- 2011-02-18 SG SG2012060893A patent/SG183356A1/en unknown
- 2011-02-18 US US13/580,105 patent/US9290572B2/en active Active
- 2011-02-18 MX MX2016011169A patent/MX375079B/es unknown
- 2011-02-18 EP EP23151118.9A patent/EP4219560A3/en not_active Withdrawn
- 2011-02-18 CN CN201510810531.1A patent/CN105315370A/zh active Pending
- 2011-02-18 MX MX2012009564A patent/MX342270B/es active IP Right Grant
- 2011-02-18 CN CN201180018213.1A patent/CN102834412B/zh not_active Expired - Fee Related
- 2011-02-18 CA CA2790488A patent/CA2790488C/en active Active
- 2011-02-18 JP JP2012554069A patent/JP2013520173A/ja active Pending
- 2011-02-18 AU AU2011217848A patent/AU2011217848B8/en not_active Ceased
-
2016
- 2016-01-21 US US15/003,642 patent/US9845357B2/en active Active
- 2016-04-13 JP JP2016079967A patent/JP6212159B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012139829A (ru) | АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8 | |
| JP6779621B2 (ja) | ＭＡｄＣＡＭアンタゴニストの投与レジメン | |
| JP2016539096A5 (enExample) | ||
| EP2623592B1 (en) | Anti-human ccr7 antibodies, hybridoma, medicinal composition, and antibody-immobilized carrier | |
| US9492569B2 (en) | Antibodies that bind integrin alpha-V beta-8 | |
| JP2019151654A (ja) | ヒト抗ｇｒｅｍ１抗体 | |
| US10124038B2 (en) | Modulators of syndecan-2 and uses thereof | |
| JP2012012402A5 (enExample) | ||
| JP2021515805A (ja) | 抗ｃｄ４７抗体及び抗ｃｄ２０抗体を使用する抗がんレジメン | |
| JP2012019790A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| WO2020223704A1 (en) | Anti-galectin-9 antibodies and uses thereof | |
| JP2015529641A5 (enExample) | ||
| JP2015501285A5 (enExample) | ||
| US9631024B2 (en) | Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors | |
| KR20140054303A (ko) | 항-Ｔｉｅ２ 항체 및 이의 용도 | |
| RS63903B1 (sr) | Antitela, upotrebe i metode | |
| TW202310870A (zh) | 用於治療造血惡性腫瘤之靶向ｃｄ７０的基因工程化免疫細胞 | |
| JP2017519757A (ja) | 慢性リンパ球性白血病（ｃｌｌ）の処置 | |
| HRP20161096T1 (hr) | Antigenski vežući proteini specifični za komponentu p serumskog amiloida | |
| WO2022204581A9 (en) | Tgf-beta inhibitors and use thereof | |
| JP2022512672A (ja) | アントラサイクリンを含む結合タンパク質－毒素融合体、および免疫腫瘍学的適用におけるその使用 | |
| JP7274454B2 (ja) | チェックポイント阻害薬のための予測末梢血バイオマーカー | |
| JP2016529213A (ja) | Ｉｌ−２１結合タンパク質及びその使用 | |
| US20230181635A1 (en) | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy |